Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC

作     者：Feifei Li Youyang Shi Mei Ma Xiaojuan Yang Xiaosong Chen Ying Xie Sheng Liu Feifei Li;Youyang Shi;Mei Ma;Xiaojuan Yang;Xiaosong Chen;Ying Xie;Sheng Liu

作者机构：Department of Breast SurgeryLonghua HospitalShanghai University of Traditional Chinese MedicineShanghai200030China Institute of Chinese Traditional SurgeryLonghua HospitalShanghai University of Traditional Chinese MedicineShanghai200030China Institute of ToxicologySchool of Public HealthLanzhou UniversityLanzhou730000China Department of General SurgeryComprehensive Breast Health CenterRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai200001China 

出 版 物：《Journal of Pharmaceutical Analysis》 (药物分析学报（英文版）)

年 卷 期：2024年第14卷第10期

页      面：1450-1467页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the National Natural Science Foundation of China(Grant No.:81774308) the Multi-center Clinical Research Project for Major Diseases of Shanghai Shenkang Hospital Development Center,China(Grant No.:SHDC2020CR1050B) the High-level University Building Innovation Team,China(Grant No.:601521D) 

主　　题：HER2-positive breast cancer Traditional chinese medicine Trastuzumab NK cell ADCC effect 

摘      要：Trastuzumab has improved survival rates in human epidermal growth factor receptor 2(HER2)-positive breast cancer(BC),but drug resistance leads to treatment *** killer(NK)cell-mediated antibody-dependent cell cytotoxicity(ADCC)represents an essential antitumor immune mechanism of *** Chinese medicine(TCM)has been used for centuries to treat diseases because of its capacity to improve immune *** Lianxia formula(XLLXF),based on the principle of“strengthening body and eliminating toxin,exhibits a synergistic effect in the trastuzumab treatment of patients with HER2-positive ***,this synergistic effect of XLLXF was executed by enhancing NK cells and ADCC,as demonstrated through in vitro co-culture of NK cells and BC cells and in vivo intervention ***,the augmented impact of XLLXF on NK cells is linked to a decrease in cytokine inducible Src homology 2(SH2)containing protein(CISH)expression,which in turn activates the Janus kinase 1(JAK1)/signal transducer and activator of transcription 5(STAT5)***,these findings suggested that XLLXF holds promise for enhancing NK cell function and sensitizing patients with HER2-positive BC to trastuzumab.